<div id="readability-page-1"><ul><li>MarketBeat Week in Review – 01/13 - 01/17</li></ul><p>Intra-Cellular Therapies, Eli Lilly and Company,  and Walmart are the three Medical stocks to watch today, according to MarketBeat's stock screener tool. Medical stocks are shares in companies that operate within the healthcare industry, including pharmaceuticals, biotechnology firms, medical device manufacturers, and healthcare service providers. They allow investors to participate in the performance and growth of companies that develop and provide products and services essential for health and wellness. These companies had the highest dollar trading volume of any Medical stocks within the last several days.</p><h2>Intra-Cellular Therapies (ITCI)</h2><p>Intra-Cellular Therapies, Inc., a biopharmaceutical company, focuses on the discovery, clinical development, and commercialization of small molecule drugs that address medical needs primarily in neuropsychiatric and neurological disorders by targeting intracellular signaling mechanisms in the central nervous system (CNS) in the United States.</p><ul><li>Is Johnson &amp; Johnson Stock Set to Reward Long-Term Holders?</li></ul><p>Shares of ITCI traded down $0.01 during midday trading on Wednesday, hitting $131.91. 16,042,154 shares of the stock were exchanged, compared to its average volume of 1,460,295. Intra-Cellular Therapies has a 52-week low of $64.09 and a 52-week high of $131.98. The stock has a fifty day simple moving average of $129.34 and a 200 day simple moving average of $100.60. The firm has a market cap of $14.05 billion, a P/E ratio of -151.62 and a beta of 0.69. </p><p>Read Our Latest Research Report on ITCI</p><h2>Eli Lilly and Company (LLY)</h2><ul><li>Bristol Myers Squibb’s big buys: $18.1 billion in 2 biotech deals</li></ul><p>Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.</p><p>Eli Lilly and Company stock traded up $4.25 during midday trading on Wednesday, reaching $809.48. 1,029,284 shares of the stock traded hands, compared to its average volume of 3,302,588. The firm has a market cap of $767.52 billion, a PE ratio of 69.13, a price-to-earnings-growth ratio of 1.40 and a beta of 0.34. The company has a current ratio of 1.15, a quick ratio of 0.97 and a debt-to-equity ratio of 2.00. The company has a 50-day simple moving average of $847.53 and a two-hundred day simple moving average of $834.15. Eli Lilly and Company has a 12-month low of $711.40 and a 12-month high of $972.53. </p><p>Read Our Latest Research Report on LLY</p><h2>Walmart (WMT)</h2><p>Walmart Inc. engages in the operation of retail, wholesale, other units, and eCommerce worldwide. The company operates through three segments: Walmart U.S., Walmart International, and Sam's Club. It operates supercenters, supermarkets, hypermarkets, warehouse clubs, cash and carry stores, and discount stores under Walmart and Walmart Neighborhood Market brands; membership-only warehouse clubs; ecommerce websites, such as walmart.com.mx, walmart.ca, flipkart.com, PhonePe and other sites; and mobile commerce applications.</p><p>Shares of WMT traded up $0.86 during mid-day trading on Wednesday, hitting $89.69. 8,797,106 shares of the company's stock were exchanged, compared to its average volume of 16,966,012. The stock's 50-day moving average is $94.45 and its 200-day moving average is $89.51. The company has a debt-to-equity ratio of 0.40, a quick ratio of 0.23 and a current ratio of 0.82. Walmart has a fifty-two week low of $58.56 and a fifty-two week high of $105.30. The company has a market cap of $719.06 billion, a price-to-earnings ratio of 37.22, a P/E/G ratio of 4.42 and a beta of 0.53. </p><p>Read Our Latest Research Report on WMT</p><h2>Recommended Stories</h2><ul><li>MarketBeat's Top Five Stocks to Own in April 2025</li><li>Homebuilders in Freefall: Bargain Opportunity or Falling Knife?</li><li>The 3 Most Talked About Investments on WallStreetBets Right Now</li><li>Analyst Targets Signal More Growth in CrowdStrike Stock</li><li>Why Howmet Could Be the Sleeper Aerospace Name of 2025</li><li>Will 2025 Be the Year the Energy Sector Finally Breaks Out?</li></ul><p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.</em></p><h2>Should You Invest $1,000 in Intra-Cellular Therapies Right Now?</h2><p>Before you consider Intra-Cellular Therapies, you'll want to hear this.</p><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Intra-Cellular Therapies wasn't on the list.</p><p>While Intra-Cellular Therapies currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.</p><p>View The Five Stocks Here</p>                  </div>

ITCI

<p>Intra-Cellular Therapies, Eli Lilly and Company, and Walmart are highlighted as key medical stocks to watch according to MarketBeat. Intra-Cellular Therapies focuses on neuropsychiatric and neurological disorders, trading at $131.91. Eli Lilly, with a market cap of $767.52 billion, trades at $809.48, offering various diabetes and obesity medications. Walmart, a retail giant, trades at $89.69, with a market cap of $719.06 billion. These stocks have shown significant trading volumes recently, indicating investor interest in the healthcare sector.</p>

- MarketBeat highlights Intra-Cellular Therapies, Eli Lilly, and Walmart as key medical stocks to monitor due to their high trading volumes.  
- Intra-Cellular Therapies focuses on neuropsychiatric drug development, while Eli Lilly offers a range of diabetes and obesity medications, and Walmart operates a vast retail and eCommerce network.  
- Each company shows significant market activity, with varying stock performance metrics, indicating their importance in the healthcare and retail sectors.

Medical Stocks To Keep An Eye On - April 2nd